Objectives and Methods: Two thirds of men with end-stage kidney disease (ESKD) have serum testosterone levels in the hypogonadal range. We examined if low serum testoster- one levels were correlated with measures of endothelial dysfunction in ESKD. Bilateral common carotid artery (CCA) intima-media thickness (IMT) and atherosclerotic plaque occurrence, left ventricular mass index, flow- (FMD) and nitrate-mediated vasodilatation (NMD) of the brachial artery were determined by ultrasound imaging in 100 nondiabetic men with ESKD (50 men exhibited androgen deficiency; serum testosterone concentrations <300 ng/dl). Results: Left-ventricular mass index, CCA diameter, CCA-IMT and atherosclerotic plaque occurrence were all significantly increased in ESKD patients with androgen deficiency compared with patients without androgen deficiency (p < 0.05). Also, FMD and NMD measurements were significantly reduced in the former compared with the latter (p < 0.05). Testosterone levels were inversely correlated with age and duration of hemodialysis therapy (r = –0.44 and r = –0.55; p < 0.001). Testosterone levels were negatively correlated to CCA-IMT and atherosclerotic plaque occurrence in patients with androgen deficiency (r = –0.32, p < 0.003, and r = –0.23, p < 0.04, respectively). FMD and NMD measurements were positively correlated to total (r = 0.65 and r = 0.61; both p < 0.0001) and free (r = 0.52 and r = 0.48; both p < 0.001) testosterone levels in patients with low androgenicity. Conclusion: The present results indicated that ESKD patients with androgen deficiency had increased CCA-IMT, atherosclerotic plaque occurrence and reduced FMD and NMD compared with patients without androgen deficiency. Testosterone serum levels were negatively correlated to CCA-IMT and positively correlated to endothelium-dependent vasodilatation in ESKD patients with androgen deficiency.

Keywords:
End-stage kidney disease, Androgen deficiency, Endothelial dysfunction, Hemodialysis
1.
Handelsman DJ, Dong Q: Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol Metab North Am 1993;22:145–159.
2.
Holdsworth J, Atkins RC, Deketser DM: The pituitary-testicular axis in men with chronic renal failure. N Engl J Med 1977;296:1245–1249.
3.
Sawin CT, Langcope C, Schmidt GW, Ryan RG: Blood levels of gonadotropins and gonadal hormones in gynecomastia associated with chronic hemodialysis. J Clin Endocrinol Metab 1973;36:988–994.
4.
Wheatley T, Clark PMS, Clark JDA, Raggatt PR, Evans D, Holder R: Pulsatility of luteinizing hormone in men with chronic renal failure: abnormal rather than absent. Br Med J 1987;294:482–483.
5.
Levitan D, Moser S, Goldstein DA, Kletzky O, Lobo R, Massry SG: Disturbances in the hypothalamic-pituitary-gonadal axis in male patients with acute renal failure. Am J Nephrol 1984;4:99–106.
6.
Woodrow G, Oldroyd B, Turney J, Tomkins L, Brownjohn A, Smith M: Whole body and regional body composition in patients with chronic renal failure. Nephrol Dial Transplant 1996;11:1613–1618.
7.
Lawrence IG, Price DE, Howlett TA, Harris KPG, Feehally J, Walls J: Correcting impotence in the male dialysis patients: experience with testosterone replacement and vacuum tumescence therapy. Am J Kidney Dis 1998;31:313–319.
8.
Pollock CA, Allen B, Warden RA, Caterson RJ, Blagojevic N, Cocksedge B, Mahony JF, Waugh DA, Ibels LS: Total body nitrogen by neutron activation in maintenance hemodialysis. Am J Kidney Dis 1990;16:38–45.
9.
Hakim R, Levin N: Malnutrition in hemodialysis patients. Am J Kidney Dis 1993;21:125–137.
10.
Lazarus J: Nutrition in hemodialysis patients. Am J Kidney Dis 1993;21:99–105.
11.
Gutman R, Stead W, Robinson R: Physical activity and employment status of patients on maintenance dialysis. N Engl J Med 1981;304:309–313.
12.
Dockery F, Bulpitt CJ, Donaldson M, Fernandez S, Rajkumar C: The relationship between androgens and arterial stiffness in older men. J Am Geriatr Soc 2003;51:1627–1632.
13.
Ahimastos AA, Formosa M, Dart AM, Kingwell BA: Gender differences in large artery stiffness pre- and post puberty. J Clin Endocrinol Metab 2003;88:5375–5380.
14.
Wenger NK, Speroff L, Packard B: Cardiovascular health and disease in women. N Engl J Med 1993;329:247–256.
15.
Lindner A, Charra B, Sherrard DJ, Scribner BH: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974;290:697–701.
16.
Luke RG: Chronic renal failure – a vasculopathic state. N Engl J Med 1998;339:841–843.
17.
Kari JA, Donald AE, Vallace DT, Bruckdorfer KR, Leone A, Mullen MJ, Bunce T, Dorado B, Deanfield JE, Rees L: Physiology and biochemistry of endothelial function in children with chronic renal failure. Kidney Int 1997;52:468–472.
18.
Van Guldener C, Lambert J, Jansen MJ, Steyn M, Donker AJ, Stehouwer CD: Endothelium dependent vasodilation is impaired in peritoneal dialysis patients. Nephrol Dial Transplant 1998;13:1782–1786.
19.
Van Guldener C, Lambert J, Jansen MJ, Donker AJ, Stehouwer CD: Endothelium dependent vasodilation and distensibility of large arteries in chronic hemodialysis patients. Nephrol Dial Transplant 1997;12(suppl 2):14–18.
20.
Joannides R, Bakkali RH, LeRoy F, Rivault O, Godin M, Moore N, Fillastre JP, Thuillez C: Altered flow dependent vaso-dilation of conduit arteries in maintenance hemodialysis. Nephrol Dial Transplant 1997;12:2623–2628.
21.
Morris ST, McMurray JJ, Rodger RS, Jardine AG: Impaired endothelium-dependent vasodilation in uremia. Nephrol Dial Transplant 2000;16:1194–2000.
22.
Karakitsos D, De Groot E, Patrianakos AP, Parthenakis F, Boletis J, Karabinis A, Kyriazis J, Vardas P, Daphnis E: Adiponectin and cardiovascular remodeling in end-stage renal disease and co-morbid diabetes mellitus. Am J Nephrol 2006;5:340–347.
23.
Singh AB, Norris K, Modi N, Sinha-Hikim I, Shen R, Davidson T, Bhasin S: Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab 2001;86:2437–2445.
24.
Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G: Survival as an index of adequacy of dialysis. Kidney Int 1992;41:1286–1291.
25.
Patrianakos A, Karakitsos D, De Groot E, Parthenakis F, Daphnis E, Vardas P: Alteration of the proximal aorta biophysical properties in patients with end-stage renal disease. Heart 2006;9:228–232.
26.
Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, et al: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two- Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358–367.
27.
Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977;55:613–618.
28.
Hoeks APG, Brands PJ, Smeets FA, Reneman RS: Assessment of distensibility of superficial arteries. Ultrasound Med Biol 1990;16:121–128.
29.
De Groot E, Hovingh K, Wiegman A, Duriez P, Smit AJ, Fruchart JC, Kastelein JJ: Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation 2004;109:33–38.
30.
Celermajer DS, Sorensen KE, Gooch VM, et al: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111–1115.
31.
Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, et al: Guidelines for ultrasound assessment of endothelium-dependent flow-mediated vasodilatation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257–265.
32.
Zadeh JA, Koutsamainis KG, Roberts AP, Curtis JR, Daly JR: The effect of maintenance hemodialysis and renal transplantation on the plasma testosterone levels of male patients in chronic renal failure. Acta Endocrinol 1975;80:577–582.
33.
Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Philips J, Dike M, Sinha-Hikim I, Shen R, Hays RD, Beall G: Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA 2000;284:763–770.
34.
Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE: Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 1996;334:150–154.
35.
Janssens SP, Shimouchi A, Quertermous T, Bloch DB, Bloch KD: Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J Biol Chem 1992;267:22694.
36.
Cooke JP: Asymmetrical dimethylarginine: the Uber marker? Circulation 2004;109:1813.
37.
Steudel W, Ichinose F, Huang PL, Hurford WE, Jones RC, Bevan JE, Fishman MC, Zapol WM: Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 1997;81:34–41.
38.
Davignon J, Ganz P: Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109:III27–III32.
39.
Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P: Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001;38:111–116.
40.
Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, Kishimoto H, Ishimura E, Tabata T, Nishizawa Y: Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001;12:2117–2124.
41.
Miyazaki H, Matsuoka H, Itabe H, Usui M, Ueda S, Okuda S, Imaizumi T: Hemodialysis impairs endothelial function via oxidative stress. Effect of vitamin E-coated dialyzer. Circulation 2001;101:1002–1006.
42.
Kosch M, Levers A, Barenbrock M, Matzkies F, Schaefer RM, Kisters K, Rahn KH, Hausberg M: Acute effects of hemodialysis on endothelial function and large artery elasticity. Nephrol Dial Transplant 2001;16:1663–1668.
43.
Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA: Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996;93:1107–1113.
44.
Sydow K, Schwedhelm E, Arakawa N, Bode-Boger SM, Tsikas D, Hornig B, Frolich JC, Boger RH: ADMA and oxidative stress are responsible for endothelial dysfunction in hyper-homocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003;57:244–252.
45.
Wada Y, Matsuoka H, Tamai O, Kohno K, Okuda S, Imaizumi T: Erythropoietin impairs endothelium-dependent vasorelaxation through cyclooxygenase-dependent mechanisms in humans. Am J Hypertens 1999;12:980–987.
46.
Schmidt RJ, Baylis C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 2000;58:1261–1266.
47.
Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572–575.
48.
Foresta C, Caretta N, Lana A, De Toni L, Biagioli A, Ferlin A, Garolla A: Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab 2006;91:4599–4602.
49.
Ghiadoni L, Cupisti A, Huang Y, Mattei P, Cardinal H, Favilla S, Rindi P, Barsotti G, Taddei S, Salvetti A: Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 2004;17:512–519.
50.
Yilmaz MI, Saglam M, Caglar K, Cakir E, Sonmez A, Ozgurtas T, Aydin A, Eyileten T, Ozcan O, Acikel C, Tasar M, Genctoy G, Erbil K, Vural A, Zoccali C: The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. Am J Kidney Dis 2006;47:42–50.
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.